Bethus, I., Tse, D., Morris, R.G., Dopamine and memory: modulation of the persistence of memory for novel hippocampal NMDA receptor-dependent paired associates. J. Neurosci. 30:5 (2010), 1610–1618.
Bockaert, J., Perroy, J., Bécamel, C., Marin, P., Fagni, L., 2010. GPCR interacting proteins (GIPs) in the nervous system: roles in physiology and pathologies. Annu. Rev. Pharmacol. Toxicol. 50 (2010), 89–109.
Conn, J., Lindsley, C., Jones, C., Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 30:1 (2009), 25–31.
Cornfield, L.J., Lambert, G., Arvidsson, L.E., Mellin, C., Vallgårda, J., Hacksell, U., Nelson, D.L., Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogs at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase. Mol. Pharmacol. 39:6 (1991), 780–787.
Dracheva, S., Elhakem, S.L., Mcgurk, S.R., Davis, K.L., Haroutunian, V., GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J. Neurosci. Res. 76:4 (2004), 581–592.
Fatemi, S.H., Stary, J.M., Earle, J.A., Araghi-Niknam, M., Eagan, E., GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr. Res. 72:2–3 (2005), 109–122.
Frankowska, M., Nowak, E., Filip, M., Effects of GABAB receptor agonists on cocaine hyperlocomotor and sensitizing effects in rats. Pharmacol. Rep. 61:6 (2009), 1042–1049.
Froestl, W., Mickel, S.J., Hall, R.G., von Sprecher, G., Strub, D., Baumann, P.A., Brugger, F., Gentsch, C., Jaekel, J., Olpe, H.R., Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J. Med. Chem. 38:17 (1995), 3297–3312.
Gannon, R.L., Millan, M.J., Positive allosteric modulators at GABAB receptors exert intrinsic actions and enhance the influence of baclofen on light-induced phase shifts of hamster circadian activity rhythms. Pharmacol. Biochem. Behav. 99:4 (2011), 712–717.
Gasbarri, A., Verney, C., Innocenzi, R., Campana, E., Pacitti, C., Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study. Brain Res. 668:1–2 (1994), 71–79.
Gasbarri, A., Sulli, A., Packard, M.G., The dopaminergic mesencephalic projections to the hippocampal formation in the rat. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 21:1 (1997), 1–22.
Gray, L., Scarr, E., Dean, B., Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. Psychiatry Res. 143:2–3 (2006), 111–120.
Guidotti, A., Auta, J., Davis, J.M., Di-Giorgi-Gerevini, V., Dwivedi, Y., Grayson, D.R., Impagnatiello, F., Pandey, G., Pesold, C., Sharma, R., Uzunov, D., Costa, E., Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 57:11 (2000), 1061–1069.
Gurevich, E.V., Joyce, J.N., Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry 42:7 (1997), 529–545.
Haracz, L., The dopamine hypothesis - an overview of studies with schizophrenia-patients. Schizophr. Bull. 8 (1982), 438–469.
Hashimoto, T., Kitamura, N., Kajimoto, Y., Shirai, Y., Shirakawa, O., Mita, T., Nishino, N., Tanaka, C., Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 112:1 Suppl (1993), S35–S39.
Heinz, A., Schlagenhauf, F., Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr. Bull. 36 (2010), 472–485.
Javitt, D.C., Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry 9:1 (1987), 12–35.
Langen, B., Dost, R., Egerland, U., Stange, H., Hoefgen, N., Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test. Psychopharmacology 221:2 (2012), 249–259.
Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:4 (2001), 402–408.
Malherbe, P., Masciadri, R., Norcross, R.D., Knoflach, F., Kratzeisen, C., Zenner, M.T., Kolb, Y., Marcuz, A., Huwyler, J., Nakagawa, T., Porter, R.H., Thomas, A.W., Wettstein, J.G., Sleight, A.J., Spooren, W., Prinssen, E.P., Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. Br. J. Pharmacol. 154:4 (2008), 797–811.
Moghaddam, B., Jackson, M.E., Glutamatergic animal models of schizophrenia. Ann N YAcad Sci 1003 (2003), 131–137.
Munch-Petersen, S., Chlorpromazine (“Largactil”) in the Management of Psychotic Patients. Acta Psychiatr. Neurol. Scand. 30 (1955), 643–658.
Noda, Y., Yamada, K., Furukawa, H., Nabeshima, T., Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br. J. Pharmacol. 116:5 (1995), 2531–2537.
Noda, Y., Mamiya, T., Furukawa, H., Nabeshima, T., Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur. J. Pharmacol. 324:2–3 (1997), 135–140.
Noda, Y., Kamei, H., Mamiya, T., Furukawa, H., Nabeshima, T., Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23:4 (2000), 375–387.
Paine, T.A., Carlezon, W.A. Jr., Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats. Neuropharmacology 56:4 (2009), 788–797.
Qiao, H., Noda, Y., Kamei, H., Nagai, T., Furukawa, H., Miura, H., Kayukawa, Y., Ohta, T., Nabeshima, T., Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12:1 (2001), 11–15.
Samara, M.T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., Leucht, S., Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiat. 73:3 (2016), 199–210.
Sumiyoshi, T., Stockmeier, C.A., Overholser, J.C., Dilley, G.E., Meltzer, H.Y., Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708:1–2 (1996), 209–214.
Thompson, R.M., Weickert, C.S., Wyatt, E., Webster, M.J., Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci. 36:3 (2011), 195–203.
Tokarski, K., Zahorodna, A., Bobula, B., Hess, G., Comparison of the effects of 5-HT1A and 5-HT4 receptor activation on field potentials and epileptiform activity in rat hippocampus. Exp. Brain Res. 147:4 (2002), 505–510.
Torrey, E.F., Barci, B.M., Webster, M.J., Bartko, J.J., Meador-Woodruff, J.H., Knable, M.B., Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry 57:3 (2005), 252–260.
Wierońska, J.M., Kusek, M., Tokarski, K., Wabno, J., Froestl, W., Pilc, A., The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice. Br. J. Pharmacol. 163:5 (2011), 1034–1047.
Wierońska, J.M., Sławińska, A., Stachowicz, K., Łasoń-Tyburkiewicz, M., Gruca, P., Papp, M., Pilc, A., The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by mGlu 2/3 receptor agonist, LY379268, in 5-HT 1A dependent. Behav. Brain Res. 256 (2013), 298–304.
Wierońska, J.M., Sławińska, A., Łasoń-Tyburkiewicz, M., Gruca, P., Papp, M., Zorn, S.H., Doller, D., Kłeczek, N., Noworyta-Sokołowska, K., Gołembiowska, K., Pilc, A., The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies. Psychopharmacology 232:1 (2015), 259–273.
Wierońska, J.M., Kłeczek, N., Woźniak, M., Gruca, P., Łasoń-Tyburkiewicz, M., Papp, M., Brański, P., Burnat, G., Pilc, A., mGlu5-GABA B interplay in animal models of positive, negative and cognitive symptoms of schizophrenia. Neurochem. Int. 88 (2015), 97–109.
Woźniak, M., Acher, F., Marciniak, M., Lasoń-Tyburkiewicz, M., Gruca, P., Papp, M., Pilc, A., Wierońska, J.M., Involvement of GABAB receptor signaling in antipsychotic-like action of the novel orthosteric agonist of the mGlu4 receptor, LSP4-2022. Curr. Neuropharmacol. 14:5 (2016), 413–426.
Woźniak, M., Gołembiowska, K., Noworyta-Sokołowska, K., Acher, F., Cieślik, P., Kusek, M., Tokarski, K., Pilc, A., Wierońska, J.M., Neurochemical and behavioral studies on the 5-HT 1A -dependent antipsychotic action of the mGlu 4 receptor agonist LSP4-2022. Neuropharmacology 115 (2017), 149–165.
